6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (s1p) receptor antagonist biological activity

Abstract

The invention provides compounds represented by the formula I, each of which compounds may have sphingosine-1-phosphate receptor agonist and or antagonist biological activity: and wherein the variables Y, R 4 , n, o, A, A 1 , A 2 , X, Z, R 1 , R 3 , R 2 , p, q and r are as defined in the specification. These compounds are useful for treating a disease or condition selected from the group consisting of glaucoma, dry eye, angiogenesis, cardiovascular conditions and diseases, and wound healing

What is claimed is: 
     
         1 . A method of treating a disease or condition selected from the group consisting of: glaucoma, dry eye, angiogenesis, cardiovascular conditions, cardiovascular diseases, and wound healing, which comprises administering to a patient in need thereof a compound having sphingosine-1-phosphate receptor biological activity represented by the general Formula I: 
       
         
           
           
               
               
           
         
       
       wherein:
 R 1  is selected from the group consisting of hydrogen, straight or branched chain alkyl having 1 to 12 carbons, heterocyclic groups having up to 20 carbon atoms and at least one of oxygen, nitrogen and/or sulfur in the ring, halo, C 1  to C 12  haloalkyl, hydroxyl, C 1  to C 12  alkoxy, C 1  to C 12  alkylcarbonyl, formyl, C 1  to C 12  alkyl carboxylate, C 1  to C 12  alkyl amide, aminocarbonyl, amino, cyano, nitro and sulfonyl groups; 
 R 2  is selected from the group consisting of hydrogen and halo; 
 R 3  is selected from the group consisting of straight or branched chain alkyl having 3 to 12 carbons, carbocyclic hydrocarbon groups having from 3 to 20 carbon atoms, heterocyclic groups having up to 20 carbon atoms and at least one of oxygen, nitrogen and/or sulfur in the ring, C 1  to C 12  alkoxy, C 1  to C 12  alkylcarbonyl and C 1  to C 12  alkyl carboxylate; 
 R 4  is selected from the group consisting of hydrogen, halo and C 1  to C 12  haloalkyl; 
 X is NR 5 ; 
 X 1  is selected from the group consisting of NR 5 , O and S; 
 R 5  is hydrogen; 
 Y is a phenyl or a pyridyl group and wherein said phenyl or pyridyl group may be bonded to A at any position; 
 Z is O; 
 n is 0 or an integer of from 1 to 5; 
 o is an integer of from 1 to 3; 
 p is 1; 
 q is 1; 
 r is 0 or 1; 
 A is selected from the group consisting of (CH 2 ) v  wherein v is an integer of from 1 to 12; 
 A 1  and A 2  are independently selected from the group consisting of (CH 2 ) v  wherein v is 0 or an integer of from 1 to 12, and branched chain alkyl having 3 to 12 carbons; 
 B is selected from the group consisting of hydrogen, OR 6 , COOR 7 , NR 8 R 9 , CONR 8 R 9 , COR 10 , CH═NOR 11 , and CH═NNR 12 R 13 ; and 
 wherein R 6 , R 7 , R 10  and R 11  are independently selected from the group consisting of hydrogen, straight or branched chain alkyl having 1 to 12 carbons, alkenyl having 2 to 6 carbons and 1 or 2 double bonds, alkynyl having 2 to 6 carbons and 1 or 2 triple bonds, a carbocyclic hydrocarbon group having from 3 to 20 carbon atoms, and a heterocyclic group having up to 20 carbon atoms and at least one of oxygen, nitrogen and/or sulfur in the ring, R 8 , R 9 , R 12  and R 13  are independently selected from the group consisting of hydrogen, straight or branched chain alkyl having 1 to 12 carbons, alkenyl having 2 to 6 carbons and 1 or 2 double bonds, alkynyl having 2 to 6 carbons and 1 or 2 triple bonds, a carbocyclic hydrocarbon group having from 3 to 20 carbon atoms, and a heterocyclic group having up to 20 carbon atoms and at least one of oxygen, nitrogen and/or sulfur in the ring, or R 8  and R 9  and/or R 12  and R 13 , together, can form a divalent carbon radical of 2 to 5 carbons to form a heterocyclic ring with nitrogen, wherein any of R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12  or R 13  may be substituted with one or more halogen, hydroxy, alkyloxy, cyano, nitro, mercapto or thiol radical; provided however, when v is 0, and r is 0, B is not hydrogen; or B is a carbocyclic hydrocarbon group having from 3 to 20 carbon atoms, or a heterocyclic group having up to 20 carbon atoms and at least one of oxygen, nitrogen and/or sulfur in the ring, and wherein when said B is a carbocyclic or heterocyclic group B may be bonded to A 2  at any position, or a pharmaceutically acceptable salt of said compound. 
 
     
     
         2 . The method according to  claim 1 , wherein A is CH 2 . 
     
     
         3 . The method according to  claim 1 , wherein n is 0 or an integer of 1 or 2 and R 4  is fluoro. 
     
     
         4 . The method according to  claim 1 , wherein R 1  is i-propyl. 
     
     
         5 . The method according to  claim 1 , wherein A 1  and A 2  are absent. 
     
     
         6 . The method according to  claim 1 , wherein B is OR 6 . 
     
     
         7 . The method according to  claim 1 , wherein B is COOR 7 . 
     
     
         8 . The method according to  claim 1 , wherein B is CH═NOR 11 . 
     
     
         9 . The method according to  claim 1 , wherein
 X 1  is O;   r is 0 or 1;   A 2  is absent or is (CH 2 ) v , wherein v is 1 or 2;   B is OR 6  or NR 8 R 9 , and R 6 , R 8  and R 9  are methyl; or   B is CH═NOR 11  and R 11  is methyl or i-butyl; or   B is CONR 8 R 9  and R 8  and R 9  are selected from the group consisting of H, methyl, ethyl and propyl or R 8  and R 9 , together with N, form a 5-membered ring; or   B is OR 6  and R 6  is H; or   B is COR 10 , and R 10  is methyl.   
     
     
         10 . A method of treating a disease or condition selected from the group consisting of: glaucoma, dry eye, angiogenesis, cardiovascular conditions, cardiovascular diseases, and wound healing, which comprises administering to a patient in need thereof a compound having sphingosine-1-phosphate receptor biological activity represented by the general Formula I: 
       
         
           
           
               
               
           
         
       
       wherein:
 R 1  is isopropyl; 
 R 2  is selected from the group consisting of hydrogen and halo; 
 R 3  is selected from the group consisting of straight or branched chain alkyl having 3 to 12 carbons, carbocyclic hydrocarbon groups having from 3 to 20 carbon atoms, heterocyclic groups having up to 20 carbon atoms and at least one of oxygen, nitrogen and/or sulfur in the ring, C 1  to C 12  alkoxy, C 1  to C 12  alkylcarbonyl and C 1  to C 12  alkyl carboxylate; 
 R 4  is selected from the group consisting of hydrogen, halo and C 1  to C 12  haloalkyl; 
 X is NR 5 ; 
 X 1  is O; 
 R 5  is hydrogen; 
 
       Y is a phenyl or a pyridyl group and wherein said phenyl or pyridyl group may be bonded to A at any position;
 Z is O; 
 n is 0 or an integer of from 1 to 5; 
 o is an integer of from 1 to 3; 
 p is 1; 
 q is 1; 
 r is 1; 
 A is selected from the group consisting of (CH 2 ) v  wherein v is an integer of from 1 to 12; 
 A 1  is absent; 
 A 2  is (CH 2 ) v , wherein v is 1 or 2; 
 B is OR 6  or NR 8 R 9 ; 
 R 6  is selected from the group consisting of hydrogen, straight or branched chain alkyl having 1 to 12 carbons, a carbocyclic hydrocarbon group having from 3 to 20 carbon atoms, and a heterocyclic group having up to 20 carbon atoms and at least one of oxygen, nitrogen and/or sulfur in the ring; 
 R 8  is selected from the group consisting of hydrogen, straight or branched chain alkyl having 1 to 12 carbons, a carbocyclic hydrocarbon group having from 3 to 20 carbon atoms, and a heterocyclic group having up to 20 carbon atoms and at least one of oxygen, nitrogen and/or sulfur in the ring; 
 R 9  is selected from the group consisting of hydrogen, straight or branched chain alkyl having 1 to 12 carbons, a carbocyclic hydrocarbon group having from 3 to 20 carbon atoms, and a heterocyclic group having up to 20 carbon atoms and at least one of oxygen, nitrogen and/or sulfur in the ring; 
 or R 8  and R 9 , together, can form a divalent carbon radical of 2 to 5 carbons to form a heterocyclic ring with nitrogen; 
 any of R 6 , R 8  and R 9  may be substituted with one or more halogen, hydroxy, alkyloxy, cyano, nitro, mercapto or thiol moiety. 
 
     
     
         11 . The method according to  claim 10 , wherein R 6 , R 8  and R 9  are methyl. 
     
     
         12 . The method according to  claim 10 , wherein B is CH═NOR 11  wherein R 11  is methyl or i-butyl. 
     
     
         13 . The method according to  claim 10 , wherein B is CONR 8 R 9  wherein R 8  and R 9  are selected from the group consisting of H, methyl, ethyl and propyl, or R 8  and R 9 , together with N, form a 5-member ring. 
     
     
         12 . The method according to  claim 10 , wherein A 1  is absent, r is 0, A 2  is CH 2  and B is OR 6 , wherein R 6  is H. 
     
     
         13 . The method according to  claim 10 , wherein A 1  is absent, r is 1 and B is COR 10  wherein R 10  is methyl.